TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Brief Summary: The purpose of the ENERGY trial is to explore whether two different programs that are focused on weight management, through increased exercise and a healthy diet, are feasible, and have an impact on body weight, quality of life and fatigue. Since obesity among breast cancer survivors is associated with recurrence and other co-morbidities, those will be assessed and their impact calculated. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: behavioral dietary intervention, Other: counseling intervention, Other: educational intervention, Other: preventative dietary intervention, Procedure: quality-of-life assessment | Arm Label: Without Counseling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: quality-of-life assessment | Intervention Type: BEHAVIORAL; Name: behavioral dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: counseling intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: OTHER; Name: preventative dietary intervention; Assigned to Arm(s): Lifestyle counseling | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Lifestyle counseling, Without Counseling
B: Arm Label: Shape-Up following cancer treatment; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Shape-Up following cancer treatment | Arm Label: Control intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shape-Up following cancer treatment; Assigned to Arm(s): Shape-Up following cancer treatment
C: Arm Label: Wait-list control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Lifestyle counseling; Type: EXPERIMENTAL; Interventions: Behavioral: behavioral dietary and exercise intervention | Intervention Type: BEHAVIORAL; Name: behavioral dietary and exercise intervention; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Less Intensive Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Less Intensive | Arm Label: Intensive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group | Intervention Type: BEHAVIORAL; Name: Less Intensive; Assigned to Arm(s): Less Intensive Group | Intervention Type: BEHAVIORAL; Name: Intensive Group; Assigned to Arm(s): Intensive Group

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reducing Breast Cancer Recurrence With Weight Loss: A Vanguard Trial
Brief Summary: The purpose of the ENERGY trial is to explore whether two different programs that are focused on weight management, through increased exercise and a healthy diet, are feasible, and have an impact on body weight, quality of life and fatigue. Since obesity among breast cancer survivors is associated with recurrence and other co-morbidities, those will be assessed and their impact calculated. Blood samples will be collected to enable analysis of potential mechanisms and differential response across subgroups.


Options:
A: Arm Label: SG-WLP; Type: OTHER; Interventions: Behavioral: SG-WLP | Arm Label: MF-WLP; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MF-WLP | Intervention Type: BEHAVIORAL; Name: MF-WLP; Assigned to Arm(s): MF-WLP | Intervention Type: BEHAVIORAL; Name: SG-WLP; Assigned to Arm(s): SG-WLP
B: Arm Label: Exercise in breast cancer survivors; Type: EXPERIMENTAL; Interventions: Behavioral: Combined aerobic and strength exercise training | Arm Label: No exercise in breast cancer survivors; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise in healthy subjects; Type: SHAM_COMPARATOR; Interventions: Behavioral: Combined aerobic and strength exercise training | Intervention Type: BEHAVIORAL; Name: Combined aerobic and strength exercise training; Assigned to Arm(s): Exercise in breast cancer survivors, Exercise in healthy subjects
C: Arm Label: Less Intensive Group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Less Intensive | Arm Label: Intensive Group; Type: EXPERIMENTAL; Interventions: Behavioral: Intensive Group | Intervention Type: BEHAVIORAL; Name: Less Intensive; Assigned to Arm(s): Less Intensive Group | Intervention Type: BEHAVIORAL; Name: Intensive Group; Assigned to Arm(s): Intensive Group
D: Arm Label: Self-regulation plus activity monitoring; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation plus activity monitoring | Arm Label: Self-regulation; Type: EXPERIMENTAL; Interventions: Behavioral: Self-regulation | Arm Label: Delayed intervention control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Self-regulation plus activity monitoring; Assigned to Arm(s): Self-regulation plus activity monitoring | Intervention Type: BEHAVIORAL; Name: Self-regulation; Assigned to Arm(s): Self-regulation

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Dose-response Study Throughout Pregnancy and Lactation
Brief Summary: Background: Vitamin D is vital throughout pregnancy and lactation for both maternal and infant health. Health Canada recommends women take the AI of 5ug/day of vitamin D during pregnancy, however, it is unknown how much vitamin D is necessary to ensure both mother and baby reach a vitamin D serum concentration of 25OHD\>75nmol/L.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: n-3 fatty acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: olive oil | Intervention Type: DIETARY_SUPPLEMENT; Name: n-3 fatty acid; Assigned to Arm(s): 1 | Intervention Type: DIETARY_SUPPLEMENT; Name: olive oil; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
C: Arm Label: 10 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 10 mcg Vitamin D3 | Arm Label: 20 mcg Vitamin D3; Type: EXPERIMENTAL; Interventions: Dietary Supplement: 20 mcg Vitamin D3 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: 10 mcg Vitamin D3; Assigned to Arm(s): 10 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: 20 mcg Vitamin D3; Assigned to Arm(s): 20 mcg Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: MMN; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Multiple micronutrient supplements (MMN) | Arm Label: IFA; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: IFA | Intervention Type: DIETARY_SUPPLEMENT; Name: Multiple micronutrient supplements (MMN); Assigned to Arm(s): MMN | Intervention Type: DIETARY_SUPPLEMENT; Name: IFA; Assigned to Arm(s): IFA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Dose-response Study Throughout Pregnancy and Lactation
Brief Summary: Background: Vitamin D is vital throughout pregnancy and lactation for both maternal and infant health. Health Canada recommends women take the AI of 5ug/day of vitamin D during pregnancy, however, it is unknown how much vitamin D is necessary to ensure both mother and baby reach a vitamin D serum concentration of 25OHD\>75nmol/L.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
B: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D
C: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3; Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A
D: Arm Label: Low dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Euro D | Arm Label: High dose vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Euro D | Intervention Type: DIETARY_SUPPLEMENT; Name: Euro D; Assigned to Arm(s): Low dose vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Euro D; Assigned to Arm(s): High dose vitamin D

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vitamin D Dose-response Study Throughout Pregnancy and Lactation
Brief Summary: Background: Vitamin D is vital throughout pregnancy and lactation for both maternal and infant health. Health Canada recommends women take the AI of 5ug/day of vitamin D during pregnancy, however, it is unknown how much vitamin D is necessary to ensure both mother and baby reach a vitamin D serum concentration of 25OHD\>75nmol/L.


Options:
A: Arm Label: Group A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group D; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol), Dietary Supplement: Placebo | Arm Label: Group E; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Vitamin D3 (cholecalciferol) | Intervention Type: DIETARY_SUPPLEMENT; Name: Vitamin D3 (cholecalciferol); Assigned to Arm(s): Group B, Group C, Group D, Group E | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Group A, Group B, Group C, Group D
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Vitamin D; Assigned to Arm(s): 3
C: Arm Label: Prenatal Vitamin D3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Prenatal Vitamin | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Prenatal Vitamin, Drug: Cholecalciferol (Vitamin D3) | Intervention Type: DRUG; Name: Prenatal Vitamin; Assigned to Arm(s): 2, 3, Prenatal Vitamin D3 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Cholecalciferol (Vitamin D3); Assigned to Arm(s): 3
D: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Arm Label: Calcium plus vitamin D; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Calcium plus vitamin D | Intervention Type: DIETARY_SUPPLEMENT; Name: Calcium plus vitamin D; Assigned to Arm(s): Calcium plus vitamin D

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Acupuncture as an Adjunct to Pulmonary Rehabilitation
Brief Summary: The hypothesis of this study was that acupuncture in conjunction with standard care of pulmonary rehabilitation improves outcome measures compared to pulmonary rehabilitation alone.


Options:
A: Arm Label: Pulmonary Rehabilitation; Type: EXPERIMENTAL; Interventions: Behavioral: Pulmonary Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Pulmonary Rehabilitation
B: Arm Label: Pulmonary Rehabilitation Group; Type: EXPERIMENTAL; Interventions: Other: Pulmonary Rehabilitation | Arm Label: Standard Care Group; Type: ACTIVE_COMPARATOR; Interventions: Other: Daily medication | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Pulmonary Rehabilitation Group | Intervention Type: OTHER; Name: Daily medication; Assigned to Arm(s): Standard Care Group
C: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture, Other: Pulmonary Rehabilitation | Arm Label: Pulmonary Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Pulmonary Rehabilitation
D: Arm Label: traditional chinese medicine; Type: EXPERIMENTAL; Interventions: Drug: Traditional Chinese Medicine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo chinese medicine | Intervention Type: DRUG; Name: Traditional Chinese Medicine; Assigned to Arm(s): traditional chinese medicine | Intervention Type: DRUG; Name: placebo chinese medicine; Assigned to Arm(s): placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Impact of Acupuncture as an Adjunct to Pulmonary Rehabilitation
Brief Summary: The hypothesis of this study was that acupuncture in conjunction with standard care of pulmonary rehabilitation improves outcome measures compared to pulmonary rehabilitation alone.


Options:
A: Arm Label: Intercom; Type: EXPERIMENTAL; Interventions: Other: INTERdisciplinary COMmunity-based COPD management (INTERCOM) | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: INTERdisciplinary COMmunity-based COPD management (INTERCOM); Assigned to Arm(s): Intercom
B: Intervention Type: BEHAVIORAL; Name: Intermediate care package; Assigned to Arm(s): N/A
C: Arm Label: Acupuncture; Type: EXPERIMENTAL; Interventions: Other: Acupuncture, Other: Pulmonary Rehabilitation | Arm Label: Pulmonary Rehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Other: Pulmonary Rehabilitation | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Acupuncture; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Acupuncture | Intervention Type: OTHER; Name: Pulmonary Rehabilitation; Assigned to Arm(s): Pulmonary Rehabilitation
D: Intervention Type: BEHAVIORAL; Name: education; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Oral dietary supplements (563 kcal/d), RESPIFOR; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercises on an ergometric bicycle 3 to 5 times a week; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: 160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 1 Randomized Double-Blind Placebo-Crossover Safety Trial of DAS181 (Fludase®) in Adult Subjects With Well-Controlled Asthma or Bronchiectasis
Brief Summary: The primary objective is to evaluate whether DAS181 is safe in subjects with well-controlled asthma or bronchiectasis.


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo Respimat | Arm Label: tiotropium low dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat low dose | Arm Label: tiotropium high dose; Type: EXPERIMENTAL; Interventions: Drug: tiotropium Respimat high dose | Intervention Type: DRUG; Name: tiotropium Respimat low dose; Assigned to Arm(s): tiotropium low dose | Intervention Type: DRUG; Name: placebo Respimat; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: tiotropium Respimat high dose; Assigned to Arm(s): tiotropium high dose
B: Arm Label: CALMA; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: CALMA plus, Behavioral: CALMA | Arm Label: Calma plus; Type: EXPERIMENTAL; Interventions: Behavioral: CALMA plus | Intervention Type: BEHAVIORAL; Name: CALMA plus; Assigned to Arm(s): CALMA, Calma plus | Intervention Type: BEHAVIORAL; Name: CALMA; Assigned to Arm(s): CALMA
C: Arm Label: Ibuprofen; Type: EXPERIMENTAL; Interventions: Drug: ibuprofen | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: ibuprofen; Assigned to Arm(s): Ibuprofen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: DAS181 Dry Powder 10 mg qd x 3 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: DAS181 dry powder, formulation F02 | Arm Label: Lactose Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Respitose ML006 (DMV-Fonterra) | Intervention Type: DRUG; Name: DAS181 dry powder, formulation F02; Assigned to Arm(s): DAS181 Dry Powder 10 mg qd x 3 days | Intervention Type: DRUG; Name: Respitose ML006 (DMV-Fonterra); Assigned to Arm(s): Lactose Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage
Brief Summary: To demonstrate that the combined used of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin alone, following vaginal birth at 36 to 42 weeks.


Options:
A: Arm Label: Oxytocin in Uniject; Type: EXPERIMENTAL; Interventions: Other: Oxytocin in Uniject | Arm Label: PPH Treatment Only; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Oxytocin in Uniject; Assigned to Arm(s): Oxytocin in Uniject
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
C: Arm Label: intravenous & intramuscular oxytocin; Type: EXPERIMENTAL; Interventions: Procedure: after delivery of the fetus & when anterior shoulder seen | Arm Label: after delivery & when anterior shoulder seen; Type: ACTIVE_COMPARATOR; Interventions: Drug: intravenous & intramuscular oxytocin | Intervention Type: DRUG; Name: intravenous & intramuscular oxytocin; Assigned to Arm(s): after delivery & when anterior shoulder seen | Intervention Type: PROCEDURE; Name: after delivery of the fetus & when anterior shoulder seen; Assigned to Arm(s): intravenous & intramuscular oxytocin
D: Arm Label: Oxytocin 10 units/500cc; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 40 units/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Oxytocin 80U/500cc; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin 10 units/500cc, Oxytocin 40 units/500cc, Oxytocin 80U/500cc

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage
Brief Summary: To demonstrate that the combined used of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin alone, following vaginal birth at 36 to 42 weeks.


Options:
A: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO
B: Arm Label: tranexamic acid; Type: ACTIVE_COMPARATOR; Interventions: Drug: transamin | Arm Label: saline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: transamin; Assigned to Arm(s): tranexamic acid
C: Arm Label: Short infusion; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin Short-infusion | Arm Label: Bolus application; Type: OTHER; Interventions: Drug: Carbetocin Bolus application | Intervention Type: DRUG; Name: Carbetocin Short-infusion; Assigned to Arm(s): Short infusion | Intervention Type: DRUG; Name: Carbetocin Bolus application; Assigned to Arm(s): Bolus application
D: Arm Label: Syntocinon; Type: ACTIVE_COMPARATOR; Interventions: Drug: Syntocinon | Arm Label: Carbetocin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carbetocin | Arm Label: Misoprostol; Type: ACTIVE_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Syntocinon; Assigned to Arm(s): Syntocinon | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Combined Use of Oxytocin and Misoprostol in the Prevention of Post Partum Haemorrhage
Brief Summary: To demonstrate that the combined used of oxytocin and misoprostol prevent from post partum haemorrhage better than oxytocin alone, following vaginal birth at 36 to 42 weeks.


Options:
A: Arm Label: Oxytocin; Type: EXPERIMENTAL; Interventions: Drug: Oxytocin | Arm Label: Carbetocin; Type: EXPERIMENTAL; Interventions: Drug: Carbetocin | Intervention Type: DRUG; Name: Carbetocin; Assigned to Arm(s): Carbetocin | Intervention Type: DRUG; Name: Oxytocin; Assigned to Arm(s): Oxytocin
B: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: UnijectTM; Type: EXPERIMENTAL; Interventions: Device: UnijectTM | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol | Intervention Type: DEVICE; Name: UnijectTM; Assigned to Arm(s): UnijectTM
C: Arm Label: Arm A: sublingual misoprostol 600µg; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: Arm B: 10 IU Oxytocin; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Arm A: sublingual misoprostol 600µg
D: Arm Label: Misoprostol; Type: EXPERIMENTAL; Interventions: Drug: Misoprostol | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Misoprostol | Intervention Type: DRUG; Name: Misoprostol; Assigned to Arm(s): Misoprostol, PLACEBO

Answer: D